Your browser doesn't support javascript.
loading
Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.
Wang, James Q; Jeelall, Yogesh S; Humburg, Peter; Batchelor, Emma L; Kaya, Sarp M; Yoo, Hee Min; Goodnow, Christopher C; Horikawa, Keisuke.
Affiliation
  • Wang JQ; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Jeelall YS; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Humburg P; Garvan Institute of Medical Research, Sydney, Australia.
  • Batchelor EL; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Kaya SM; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Yoo HM; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Goodnow CC; Garvan Institute of Medical Research, Sydney, Australia c.goodnow@garvan.org.au.
  • Horikawa K; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia keisuke.horikawa@anu.edu.au.
J Exp Med ; 214(9): 2759-2776, 2017 Sep 04.
Article in En | MEDLINE | ID: mdl-28701369
CD79B and MYD88 mutations are frequently and simultaneously detected in B cell malignancies. It is not known if these mutations cooperate or how crosstalk occurs. Here we analyze the consequences of CD79B and MYD88L265P mutations individually and combined in normal activated mouse B lymphocytes. CD79B mutations alone increased surface IgM but did not enhance B cell survival, proliferation, or altered NF-κB responsive markers. Conversely, B cells expressing MYD88L265P decreased surface IgM coupled with accumulation of endoglycosidase H-sensitive IgM intracellularly, resembling the trafficking block in anergic B cells repeatedly stimulated by self-antigen. Mutation or overexpression of CD79B counteracted the effect of MYD88L265P In B cells chronically stimulated by self-antigen, CD79B and MYD88L265P mutations in combination, but not individually, blocked peripheral deletion and triggered differentiation into autoantibody secreting plasmablasts. These results reveal that CD79B and surface IgM constitute a rate-limiting checkpoint against B cell dysregulation by MYD88L265P and provide an explanation for the co-occurrence of MYD88 and CD79B mutations in lymphomas.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin M / Receptor Cross-Talk / CD79 Antigens / Myeloid Differentiation Factor 88 Limits: Animals Language: En Journal: J Exp Med Year: 2017 Document type: Article Affiliation country: Australia Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin M / Receptor Cross-Talk / CD79 Antigens / Myeloid Differentiation Factor 88 Limits: Animals Language: En Journal: J Exp Med Year: 2017 Document type: Article Affiliation country: Australia Country of publication: United States